Publications by authors named "Emmanuela Bovo"
Article Synopsis
- VEGF plays a crucial role in therapeutic angiogenesis, but its effectiveness is compromised by the need for short-term delivery due to safety concerns, leading to unstable new blood vessels.
- Research using transduced myoblasts in SCID mouse muscles revealed that low doses of VEGF promote faster vessel stabilization, while high doses delay it, without affecting pericyte coverage.
- The study found that high VEGF levels inhibit endothelial Semaphorin3A expression, disrupting the recruitment of specific monocytes necessary for vessel stabilization, but Semaphorin3A treatment can counteract this effect even with high VEGF doses.
Blood vessel growth plays a key role in regenerative medicine, both to restore blood supply to ischemic tissues and to ensure rapid vascularization of clinical-size tissue-engineered grafts. For example, vascular endothelial growth factor (VEGF) is the master regulator of physiological blood vessel growth and is one of the main molecular targets of therapeutic angiogenesis approaches. However, angiogenesis is a complex process and there is a need to develop rational therapeutic strategies based on a firm understanding of basic vascular biology principles, as evidenced by the disappointing results of initial clinical trials of angiogenic factor delivery.
View Article and Find Full Text PDF